Watch for initiation of the planned Phase 2 trial in older adults with obesity and decreased muscle mass/strength, and any partnership or licensing interest from GLP-1 developers seeking combination therapies. The Lancet publication adds credibility.
Price Chart
Executive Summary
Regeneron announced positive Phase 2 COURAGE trial results for trevogrumab (anti-myostatin) showing preservation of lean mass and muscle during semaglutide-induced weight loss in obesity patients. The 75 mg dose preserved 50.7% of lean mass at 26 weeks and 42.5% at 52 weeks vs placebo, with MRI data showing ~70% thigh muscle preservation. Regeneron plans to initiate a Phase 2 trial in older adults with obesity and decreased muscle mass/strength. The data is in press with The Lancet and was presented at EASD.
Key Facts
- Trevogrumab 75 mg + semaglutide preserved 50.7% of lean mass at 26 weeks and 42.5% at 52 weeks vs placebo + semaglutide
- MRI data showed ~70% preservation of thigh muscle volume that would have been lost with semaglutide alone
- Regeneron plans to initiate a Phase 2 trial in older adults with obesity and decreased muscle mass/strength
- Results presented at EASD Annual Meeting and in press with The Lancet
- Lower doses of trevogrumab were generally well tolerated (77% AE rate vs 82% placebo)
Financial Impact
Positive Phase 2 data supports trevogrumab's potential to address muscle loss in GLP-1 obesity market, a large and growing therapeutic area. No financial figures provided.
Risk Factors
- Trevogrumab has not been evaluated by any regulatory authority; Phase 3 trials and regulatory approval are years away
- Competing muscle-preservation approaches from other companies may emerge
- Combination with GLP-1s requires co-development partnerships or licensing
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3373155 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | Press Release | $807.67 | awaiting T+5 | — | $816.10 (+1.04%) |
Oct 25, 2026 2d ago | Press Release | $807.67 | awaiting T+5 | — | $816.10 (+1.04%) |
Oct 23, 2026 4d ago | Institutional Cluster | $805.02 | awaiting T+5 | — | $816.10 (−1.38%) |
Oct 15, 2026 12d ago | ANALYST-UPGRADE | $790.74 $805.02 | ▲ +1.81% | ▲ +2.24% | $816.10 (+3.21%) |
Oct 14, 2026 13d ago | 144 | $796.34 $819.09 | ▲ +2.86% | ▲ +3.87% | $816.10 (+2.48%) |
Oct 6, 2026 21d ago | 8-K | $738.72 $753.12 | ▲ +1.95% | ▲ +2.09% | $816.10 (+10.47%) |
Oct 1, 2026 26d ago | Press Release | $734.81 $739.57 | ▲ +0.65% | ▼ −0.65% | $816.10 (+11.06%) |
Oct 1, 2026 26d ago | Press Release | $734.81 $739.57 | ▲ +0.65% | ▼ −0.65% | $816.10 (+11.06%) |
Oct 1, 2026 26d ago | ANALYST-UPGRADE | — | awaiting T+5 | — | — |
Oct 1, 2026 27d ago | Press Release | $734.81 $739.57 | ▲ +0.65% | ▼ −0.65% | $816.10 (+11.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers